Healthpeak Properties: Can This Healthcare REIT Keep Funding Its Dividend

Healthpeak's $1.22004 annualized dividend, yielding 6.48%, is covered at about 69.7% of midpoint 2026 adjusted FFO guidance of $1.73–$1.77 per share, though the article flags a shrinking cushion. Liquidity was $3.4B as of August 3, while quarterly interest expense rose to $92.3M from $75.1M and net debt to adjusted EBITDAre was 5.2x at year-end 2025. Senior-housing NOI growth is offsetting lab-space weakness; the key tripwire is any FY2026 adjusted FFO guidance below $1.73.

Analysis

The key risk is not the stated FFO payout ratio in isolation; it is whether recurring cash after leasing costs, maintenance capex and JV-level obligations can support both the dividend and capital returns without further asset sales. Selling a stake in outpatient properties improves near-term liquidity and reduces refinancing pressure, but also gives up part of a relatively occupied, steadier rent stream. Track retained cash flow and net debt—not headline sale proceeds—as the test of whether this is genuine deleveraging or balance-sheet support bought with future income.

DOC’s portfolio now has a meaningful mismatch: senior housing is the growth engine, while lab weakness constrains total NOI. A slow biotech funding recovery could prolong lab vacancy and concessions, making senior-housing growth insufficient to restore consolidated growth. Conversely, stronger senior housing can benefit Janus Living (JAN), but DOC investors only capture that through its ownership and reported contribution; do not treat JAN’s operating upside as equivalent to DOC-wide growth.

The dividend appears covered on the supplied adjusted-FFO measure, but that is not a guarantee of cash available for distribution. Rising interest expense and the history of prior cuts make a downgrade in guidance more consequential than the current yield is reassuring. The $500 million buyback also competes with debt reduction for capital; its value depends on repurchase price and whether leverage is falling.

Near term, price action may remain yield-driven. Over 1–3 months, guidance, lab leasing and debt disclosures are the catalysts. Over 6–18 months, lab absorption and senior-housing execution determine whether DOC’s weak consolidated growth is temporary. Relative preference for WELL and VTR is supported by stronger disclosed operating momentum, but valuation and balance-sheet comparisons are still needed before sizing a pair.

Key Decisions for Investors

• Do not buy DOC solely for its yield. Keep it on watch pending confirmation that FY2026 adjusted FFO guidance remains at or above the stated low end and that recurring cash flow—not additional asset sales—covers distributions and investment needs.
• For an income-oriented relative-value screen, compare DOC against WELL and VTR; consider a small DOC-underweight / WELL-or-VTR-overweight only after checking relative valuation, leverage, and dividend coverage on comparable definitions. Falsify the underweight if DOC raises guidance, lab occupancy stabilizes, and net debt declines without material further disposals.
• At the next results, verify lab leasing spreads, occupancy and concessions; senior-housing NOI contribution; AFFO or equivalent after recurring capex; debt maturities and interest-rate exposure; and the cash-flow effect of the outpatient JV sale. A guidance cut below $1.73 or worsening lab leasing would strengthen the downside case.
• Treat the buyback as a capital-allocation watch item, not a bullish signal by itself. It is constructive if executed at an attractive price while leverage falls; it is a negative if repurchases coincide with rising net debt or renewed asset sales.